Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Average Rating of "Hold" from Analysts

Key Points

• Smith & Nephew SNATS, Inc. (NYSE:SNN) currently holds an average analyst rating of "Hold" from six brokerages, reflecting a consensus view among analysts.
• Canaccord Genuity recently increased its price target for the stock from $28.00 to $36.00, while HSBC downgraded its rating from "buy" to "hold."
• The company announced a semi-annual dividend of $0.285, with a dividend payout ratio of 41.20%, scheduled for payment on November 7th.

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) has been given an average recommendation of "Hold" by the six brokerages that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $36.00.

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group raised their price objective on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research note on Monday. HSBC cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Hsbc Global Res cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th.

Institutional Trading of Smith & Nephew SNATS

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Evergreen Capital Management LLC increased its holdings in shares of Smith & Nephew SNATS by 37.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 11,936 shares of the medical equipment provider's stock valued at $366,000 after acquiring an additional 3,276 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Smith & Nephew SNATS by 507.8% in the second quarter. Tower Research Capital LLC TRC now owns 355,913 shares of the medical equipment provider's stock worth $10,902,000 after purchasing an additional 297,359 shares in the last quarter. Corient Private Wealth LLC grew its stake in shares of Smith & Nephew SNATS by 100.8% in the second quarter. Corient Private Wealth LLC now owns 47,388 shares of the medical equipment provider's stock worth $1,451,000 after purchasing an additional 23,788 shares in the last quarter. Vident Advisory LLC grew its stake in shares of Smith & Nephew SNATS by 28.8% in the second quarter. Vident Advisory LLC now owns 19,855 shares of the medical equipment provider's stock worth $608,000 after purchasing an additional 4,445 shares in the last quarter. Finally, Orion Porfolio Solutions LLC bought a new position in shares of Smith & Nephew SNATS in the second quarter worth $237,000. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Performance

SNN stock opened at $36.51 on Monday. The firm has a market cap of $15.99 billion, a price-to-earnings ratio of 16.92, a PEG ratio of 1.00 and a beta of 0.68. The firm has a 50-day simple moving average of $31.24 and a two-hundred day simple moving average of $28.87. Smith & Nephew SNATS has a one year low of $23.69 and a one year high of $36.84. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Smith & Nephew SNATS Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be issued a $0.285 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a yield of 210.0%. Smith & Nephew SNATS's dividend payout ratio is 41.20%.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.